Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2021-09-07 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CFO of PharmaTher Holdings Ltd. It certifies the review and fair presentation of the annual filings for the financial year ended May 31, 2021. The text explicitly states it is a certification document related to annual filings, not the filings themselves. It includes disclaimers about the scope of the certification and internal controls. The document length is 3227 characters, which is relatively short and consistent with a certification letter rather than a full annual report or financial statement. According to the CERTIFICATION RULE, documents that are primarily officer certifications or attestations, even if referencing annual filings, should be classified as Regulatory Filings (RNS) rather than as the report itself (e.g., 10-K or Annual Report). Therefore, this document is best classified as a Regulatory Filing (RNS).
2021-09-07 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the year ended May 31, 2021, dated September 7, 2021. It contains detailed management commentary on the company's financial condition, operating performance, forward-looking statements, risk factors, and business overview. The text references compliance with National Instrument 51-102 and IFRS accounting standards, indicating it is a formal financial disclosure document. The length of the document (15,000 characters) and the presence of substantive financial and operational discussion confirm it is a full report rather than a brief announcement or certification. Therefore, this document fits the category of Management Reports (MDA), which are detailed explanations of financial results and business trends by management, distinct from the full Annual Report (10-K) or Earnings Release (ER).
2021-09-07 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Management Certification related to Form 13-502F1, which is a regulatory form submitted to the Ontario Securities Commission concerning participation fees for reporting issuers. It contains officer certification statements, market value calculations, and fee details. There are no financial statements or substantive financial data typical of annual or interim reports. The document is primarily a certification and regulatory submission rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance document and officer attestation.
2021-09-07 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is titled as "INDEPENDENT AUDITOR’S REPORT" for PharmaTher Holdings Ltd. and includes detailed consolidated financial statements for the year ended May 31, 2021, and the period from April 1, 2020 (date of incorporation) to May 31, 2020. It contains the auditor's opinion, basis for opinion, material uncertainty related to going concern, responsibilities of management and auditors, and detailed financial statements including statements of financial position, income, changes in equity, and cash flows. The content is a full audit report with financial data and notes, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR). FY 2021
2021-09-07 English
News release - English.pdf
Regulatory Filings
2021-08-05 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of a provisional patent application for a novel ketamine formulation by PharmaTher Holdings Ltd. It discusses the company's intellectual property portfolio, clinical programs, and strategic positioning in the psychedelics biotech sector. There are no financial statements, regulatory filings, or detailed financial data presented. The content focuses on intellectual property and business development rather than financial results or governance. It is not an Annual Report, Earnings Release, or any other financial or regulatory filing. The document is a corporate announcement about patent filing and business strategy, which does not fit into the specific categories related to financial or regulatory reports. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-07-21 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.